Madrigal Pharmaceuticals, Inc. - MDGL Quarterly Revenue Growth

Madrigal Pharmaceuticals, Inc. (MDGL) - corporate logo

Madrigal Pharmaceuticals (MDGL) holds a monopoly in the NASH niche thanks to Rezdiffra, limited only by geopolitical risks capable of disrupting tests and supplies. This chart from the GURU.Markets terminal illustrates the percentage growth of quarterly revenue, where 50.40 expresses the current value of the metric. The business relies on an asset-light model, outsourcing drug production to third-party plants, which makes the company's stability dependent on external contractors.

MDGL Madrigal Pharma Quarterly Sales Growth Rate (07/04/2022 - 11/20/2026)

MDGL (Madrigal Pharmaceuticals, Inc.): analytical breakdowns and indicator data

- current quotes and average value forecast:
- cash and cash flow indicators:
Analysis of all company metrics:Madrigal Pharmaceuticals, Inc. (MDGL)
Mass-produced product of madrigalpharma.com

For Madrigal Pharmaceuticals (MDGL), sales momentum determines the success of the first specialized drug's market launch. This metric is calculated as the percentage change in revenue for the current quarter relative to the previous one, measuring the speed of commercial expansion. By analyzing the quarterly revenue dynamics, an investor assesses the effectiveness of the drug's integration into medical practice. High data volatility reflects the cash flow formation stage and the issuer's overall financial uncertainty.

Direct competitors

ASND - Revenue Growth QoQ|CORT: Revenue Growth QoQ|RYTM: Quarterly Revenue Growth|AKRO - Quarterly Sales Growth Rate|Revenue Growth QoQ Metsera Therapeutics|MoonLake Corp (MLTX) - Quarterly Sales Growth Rate|Revenue Growth QoQ crinetics.com (CRNX)|Quarterly Sales Growth newamsterdampharma.com NAMS|Revenue Growth QoQ Soleno Therapeutics Inc SLNO|Quarterly Revenue Growth Amicus Therapeutics Inc FOLD|89bio Corp - Quarterly Revenue Growth|Revenue Change vs Previous Quarter Agios Pharmaceuticals Inc (AGIO)|Structure Therapeutics (GPCR) - Revenue Growth QoQ|Quarterly Sales Growth MiMedx Group, Inc.|Revenue Growth QoQ Rezolute Bio|Lexicon Pharmaceuticals, Inc. (LXRX) - Quarterly Sales Growth Rate|Quarterly Revenue Growth MBX|Quarterly Sales Growth Altimmune, Inc. ALT|Quarterly Revenue Growth AARD (Aardvark Pharma)|Sagimet Biosciences Inc. (SGMT) - Quarterly Revenue Growth Rate|BIOA: Quarterly Sales Growth|Quarterly Revenue Increase BMEA (Biomea Fusion)|QNCX (quincetx.com) - Quarterly Sales Growth|Fractyl - Quarterly Revenue Increase|VTVT (vTv Therapeutics Inc) - Quarterly Revenue Growth|Agape ATP - Revenue Dynamics QoQ|Quarterly Sales Growth PLUR (Pluri Inc)|Quarterly Sales Growth Rate Synlogic Inc.|Revenue Growth QoQ Lipocine Inc. LPCN|Matinas BioPharma (MTNB) - Quarterly Revenue Growth Rate|Spruce Biosciences Inc. - Quarterly Revenue Growth|Quarterly Sales Growth Rate Galecto, Inc. GLTO|Carmell Therapeutics (CTCX) - Revenue Growth QoQ|Lumos Pharma - Quarterly Revenue Increase|ONVO (Organovo Corp) - Quarterly Revenue Growth|Radius Pharmaceuticals (RDUS) - Quarterly Sales Growth Rate